Long term outcomes after repeat lymph node dissections for persistent or recurrent differentiated thyroid cancer - 13/12/24
Abstract |
Background |
The primary treatment for locoregional recurrent/persistent differentiated thyroid cancer (DTC) is repeated lymph node dissection; however, there are limited reports on the safety and long-term efficacy of multiple operations.
Methods |
Patients who underwent a cervical lymph node dissection between 1998 and 2022 were included in this study. Demographics, initial thyroid surgery, subsequent lymph node dissections, follow up information, and response to therapy were acquired.
Results |
After one, two, three and four re-operations, 112/314 (35.7 %), 16/79 (20.3 %), 3/25 (12 %), and 0/3 (0 %) patients (p < 0.001) had an excellent response, respectively, resulting in a cumulative rate of 41.7 % (131/314). The risk for permanent hypoparathyroidism (2.9 %) or recurrent laryngeal nerve injury (2.2 %) was 5.1 % (14/272). This was higher in patients undergoing re-operative central neck dissection (CNDx) (8.7 %, 10/114) versus those who did not undergo a previous CNDx (2.5 %, 4/158, p < 0.02).
Conclusions |
Surgery remains the primary treatment for recurrent/persistent DTC, however, the likelihood of an excellent response decreases with additional operations. The risk of permanent complications is low but is more likely to occur during redo CNDx.
Le texte complet de cet article est disponible en PDF.Highlights |
• | The likelihood of an excellent response for thyroid cancer decreases with each additional cervical lymph node operation. |
• | The overall risk for permanent hypoparathyroidism (2.9 %) or recurrent laryngeal nerve injury (2.2 %) was 5.1 %. |
• | The risk of these complications was higher in patients undergoing re-operative central neck dissection. |
Keywords : Thyroid cancer, Neck dissection, Response to therapy
Plan
Vol 239
Article 116045- janvier 2025 Retour au numéro
Article précédent
- Healthcare disparities in access to surgical management and outcomes of patients with nonmetastatic primary liver cancer: A population based study from Louisiana tumor registry
- McKenzie Hargis, Aimée Galatas, Denise Danos, Hannah R. Malinosky, Sydney McManus, Kevin Sullivan, Mohammad Al Efishat, John Lyons, James C. Watson, Mary Maluccio, Omeed Moaven
- Examining the false-negative rate of a negative axillary node ultrasound-guided core needle biopsy in breast cancer patients undergoing upfront surgery
- Christine Rogers, Sarah Zeien, Kaleen Puccetti, Julie M. Jorns, Amanda L. Kong, Solomon Cherian, Chandler S. Cortina
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?